SOUTH SAN FRANCISCO, Calif., Feb. 26 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has named Daniel B. Magilavy, M.D. vice president of clinical research. In this newly created position, Dr. Magilavy will be responsible for the direction and oversight of Rigel's clinical research programs in rheumatoid arthritis (RA), and related autoimmune disorders. Rigel's R788, oral syk kinase inhibitor, is expected to enter advanced Phase 2 clinical studies for RA and ITP this year, and also a Phase 2 clinical study in systemic lupus erythematosus. In addition, Rigel's oral JAK3 inhibitor, R348, is currently in a Phase 1 study for the potential treatment of psoriasis and RA.
"Dan comes to Rigel with solid clinical research leadership experience and expertise in the medical subspecialties for which we are developing drugs," said Elliott B. Grossbard, M.D., Rigel's executive vice president and chief medical officer. "I look forward to working with him as we continue to expand our clinical research programs," he added.
Dr. Magilavy most recently served as Senior Medical Director at Genzyme, Inc. He began his career in the biopharmaceutical industry as Director of Medical Research at Biogen, Inc. from 1994-2000. In these positions, Dr. Magilavy interacted with preclinical and clinical research organizations, various regulatory agencies, and was integral to the decision making processes relating to new drug development.
Dr. Magilavy received his M.D. from Ohio State University in 1972 and
was most recently a lecturer in the Department of Pediatrics of Harvard
Medical School. Prior to that he was Associate Professor of Pediatrics and
Immunology, and Director of the Section of Rheumatology
|SOURCE Rigel Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved